nach oben

Erschienen in:

09.07.2024 | Urologic Oncology

Radiotherapy Versus Partial Penectomy for T1 Squamous Cell Carcinoma of the Penis

verfasst von: Letizia Maria Ippolita Jannello, MD, Carolin Siech, MD, Mario de Angelis, MD, Francesco Di Bello, MD, Natali Rodriguez Peñaranda, MD, Zhe Tian, MSc, Jordan A. Goyal, MS, Stefano Luzzago, MD, Francesco A. Mistretta, MD, Emanuele Montanari, MD, Fred Saad, MD, PhD, Felix K. H. Chun, MD, PhD, Alberto Briganti, MD, PhD, Salvatore Micali, MD, Nicola Longo, MD, Ottavio de Cobelli, MD, Gennaro Musi, MD, Pierre I. Karakiewicz, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Radiotherapy (RT) represents an alternative treatment option for patients with T1 squamous cell carcinoma of the penis (SCCP), with proven feasibility and tolerability. However, it has never been directly compared with partial penectomy (PP) using cancer-specific mortality (CSM) as an end point.

Methods

In the Surveillance, Epidemiology, and End Results database (2000–2020), T1N0M0 SCCP patients treated with RT or PP were identified. This study relied on 1:4 propensity score-matching (PSM) for age at diagnosis, tumor stage, and tumor grade. Subsequently, cumulative incidence plots as well as multivariable competing risks regression (CRR) models addressed CSM. Additionally, the study accounted for the confounding effect of other-cause mortality (OCM).

Results

Of 895 patients with T1N0M0 SCCP, 55 (6.1%) underwent RT and 840 (93.9%) underwent PP. The RT and PP patients had a similar age distribution (median age, 70 vs 70 years) and more frequently harbored grade I or II tumors (67.3% vs 75.8%) as well as T1a-stage disease (67.3% vs 74.3%). After 1:4 PSM, 55 (100%) of the 55 RT patients versus 220 (26.2%) of the 840 PP patients were included in the study. The 10-year CSM derived from the cumulative incidence plots was 25.4% for RT and 14.4% for PP. In the multivariable CRR models, RT independently predicted a higher CSM than PP (hazard ratio, 1.99; 95% confidence interval, 1.05–3.80; p = 0.04).

Conclusion

For the T1N0M0 SCCP patients treated in the community, RT was associated with nearly a twofold higher CSM than PP. Ideally, a validation study based on tertiary care institution data should be conducted to test whether this CSM disadvantage is operational only in the community or not.

Wenzel M, et al. Temporal trends, tumor characteristics, and stage-specific survival in penile non-squamous cell carcinoma vs squamous cell carcinoma”. Cancer Causes Control. 2022;33:25–35. https://doi.org/10.1007/s10552-021-01493-3.CrossRef

Sharma P, Ashouri K, Zargar-Shoshtari K, Luchey AM, Spiess PE. Racial and economic disparities in the treatment of penile squamous cell carcinoma: results from the National Cancer Database. Urol Oncol Semin Orig Investig. 2016;34:122.e9-122.e15. https://doi.org/10.1016/j.urolonc.2015.10.001.CrossRef

Kamel MH, et al. Survival outcomes of organ-sparing surgery, partial penectomy, and total penectomy in pathological T1/T2 penile cancer: report from the National Cancer Data Base. Urol Oncol Semin Orig Investig. 2018;36(82):e7–15. https://doi.org/10.1016/j.urolonc.2017.10.017.CrossRef

Crook JM, Haie-Meder C, Demanes DJ, Mazeron JJ, Martinez AA, Rivard MJ. American Brachytherapy Society-Groupe Européen de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy. 2013;12:191–8. https://doi.org/10.1016/j.brachy.2013.01.167.CrossRef

Rozan R, et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol. 1995;36:83–93. https://doi.org/10.1016/0167-8140(95)01574-Z.CrossRef

Pohanková D, et al. High-dose-rate brachytherapy as an organ-sparing treatment for early penile cancer. Cancers Basel. 2022. https://doi.org/10.3390/cancers14246248.CrossRefPubMedCentral

Azrif M, Logue JP, Swindell R, Cowan RA, Wylie JP, Livsey JE. External-beam radiotherapy in T1–2 N0 penile carcinoma. Clin Oncol. 2006;18:320–5. https://doi.org/10.1016/j.clon.2006.01.004.CrossRef

Martz N, et al. High-dose rate brachytherapy in localized penile cancer: 5-year clinical outcome analysis. Clin Transl Radiat Oncol. 2021;27:89–95. https://doi.org/10.1016/j.ctro.2020.12.008.CrossRefPubMedCentral

Kellas-Ślęczka S, et al. Nineteen-year single-center experience in 76 patients with penile cancer treated with high-dose-rate brachytherapy. Brachytherapy. 2019;18:493–502. https://doi.org/10.1016/j.brachy.2019.03.006.CrossRef

10.

Marbán M, Crook J, Keyes M, Dubash R, Batchelar D. High-dose-rate brachytherapy for localized penile cancer: evolution of a technique. Brachytherapy. 2020;19:201–9. https://doi.org/10.1016/j.brachy.2019.12.003.CrossRef

11.

Sharma DN, et al. High-dose-rate interstitial brachytherapy for T1–T2-stage penile carcinoma: short-term results. Brachytherapy. 2014;13:481–7. https://doi.org/10.1016/j.brachy.2014.06.003.CrossRef

12.

Kiltie AE, Elwell C, Close HJ, Ash DV. Iridium-192 implantation for node-negative carcinoma of the penis: the Cookridge Hospital experience. Clin Oncol. 2000;12:25–31. https://doi.org/10.1053/clon.2000.9106.CrossRef

13.

SEER. SEER Cancer Statistics Review, 1975–2020. https://seer.cancer.gov/index.html. Accessed 12 Jan 2024.

14.

Piccinelli ML, et al. Critical appraisal of Leibovich 2018 and GRANT models for prediction of cancer-specific survival in non-metastatic chromophobe renal cell carcinoma. Cancers Basel. 2023. https://doi.org/10.3390/cancers15072155.CrossRefPubMedCentral

15.

Piccinelli ML, et al. Assessment of the VENUSS and GRANT models for individual prediction of cancer-specific survival in surgically treated nonmetastatic papillary renal cell carcinoma. Eur Urol Open Sci. 2023;53:109–15. https://doi.org/10.1016/j.euros.2023.05.005.CrossRefPubMedCentral

16.

R: the R project for statistical computing. https://www.r-project.org/. Accessed 4 Jan 2024.

17.

Loughlin KR. Penile cancer. Curr Opin Urol. 1993;3:415–7. https://doi.org/10.1097/00042307-199310000-00016.CrossRef

18.

Ayres B, et al. EAU-ASCO collaborative guidelines on penile cancer. Eur Assoc Urol Am Soc Clin Oncol. 2023;84:7–36.

19.

Mulherkar R, et al. National patterns of care for early-stage penile cancers in the United States: how is radiation and brachytherapy utilized? Brachytherapy. 2019;18:503–9. https://doi.org/10.1016/j.brachy.2019.04.007.CrossRef

20.

Spiess PE. New treatment guidelines for penile cancer. J Natl Compr Cancer Netw. 2013;11:659–62. https://doi.org/10.6004/jnccn.2013.0195.CrossRef

21.

Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol. 2009;27:189–96. https://doi.org/10.1007/s00345-008-0309-5.CrossRef

22.

de Angelis M, et al. Cancer-specific mortality in non-metastatic T1a renal cell carcinoma treated with radiotherapy versus partial nephrectomy. World J Urol. 2024;42:193. https://doi.org/10.1007/s00345-024-04856-y.CrossRef

23.

Mistretta FA, et al. Conditional survival of patients with stage I–III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. World J Urol. 2020;38:725–32. https://doi.org/10.1007/s00345-019-02869-6.CrossRef

24.

Tappero S, et al. Effect of inguinal lymph node dissection in lymph node-negative patients with squamous cell carcinoma of the penis. World J Urol. 2023;41:119–25. https://doi.org/10.1007/s00345-022-04184-z.CrossRef

Titel: Radiotherapy Versus Partial Penectomy for T1 Squamous Cell Carcinoma of the Penis
verfasst von: Letizia Maria Ippolita Jannello, MD
Carolin Siech, MD
Mario de Angelis, MD
Francesco Di Bello, MD
Natali Rodriguez Peñaranda, MD
Zhe Tian, MSc
Jordan A. Goyal, MS
Stefano Luzzago, MD
Francesco A. Mistretta, MD
Emanuele Montanari, MD
Fred Saad, MD, PhD
Felix K. H. Chun, MD, PhD
Alberto Briganti, MD, PhD
Salvatore Micali, MD
Nicola Longo, MD
Ottavio de Cobelli, MD
Gennaro Musi, MD
Pierre I. Karakiewicz, MD
Publikationsdatum: 09.07.2024
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 9/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-15767-y

ASO Author Reflections: Benefits of Surgical Resection of Perihilar Cholangiocarcinoma with Positive Peritoneal Lavage Cytology

ASO Author Reflections

Therapeutic Strategy by Neuronal Pentraxin Receptor for Esophageal Squamous Cancer Cells

Thoracic Oncology

ASO Author Reflections: Neoadjuvant Chemotherapy in cT2N0M0 Gastric Cancer; Time to Revisit Current Recommendations?

Open Access
ASO Author Reflections

ASO Author Reflections: Application and Prospect of Patient-Reported Outcomes in Enhanced Recovery After Esophagectomy for Cancer

ASO Author Reflections

The Effects of Various Approaches to Lobectomies on Respiratory Muscle Strength, Diaphragm Thickness, and Exercise Capacity in Lung Cancer

Open Access
Thoracic Oncology

Enhanced Recovery Protocol Versus Conventional Care in Patients Undergoing Esophagectomy for Cancer: Advantages in Clinical and Patient-Reported Outcomes

Thoracic Oncology

Neu im Fachgebiet Chirurgie

Akute Cholezystitis bei multimorbiden Älteren: Operation nicht sofort ausschließen!

16.04.2025
Operationen an Gallenblase und Gallenwegen
Nachrichten

Bei älteren, multimorbiden Menschen mit akuter Cholezystitis wird eine Operation häufig nicht erwogen. Eine Studie aus Philadelphia zeigt nun jedoch, dass auch diese Patientinnen und Patienten von einer chirurgischen Therapie profitieren können.

Was geschehen muss, damit Prähabilitation in die Leitlinien kommt

08.04.2025
DCK 2025
Nachrichten

Eine Prähabilitation vor einem viszeralchirurgischen Eingriff ist Experten zufolge äußerst sinnvoll, dennoch wird sie in Leitlinien derzeit nicht empfohlen. Beim DCK erklärte Prof. Tim Vilz aus Bonn, woran das liegt und was benötigt wird, um die Situation zu ändern.

Thoracic-Outlet-Syndrom nur in Ausnahmefällen operieren!

08.04.2025
DCK 2025
Nachrichten

Das Thoracic-Outlet-Syndrom erfordert nur in ganz bestimmten Fällen ein operatives Vorgehen. Beim DCK wurde vor schwerwiegenden Komplikationen des anspruchsvollen Eingriffs gewarnt.

Statine: Was der G-BA-Beschluss für Praxen bedeutet

06.04.2025
Praxis und Beruf
Nachrichten

Nach dem G-BA-Beschluss zur erweiterten Verordnungsfähigkeit von Lipidsenkern rechnet die DEGAM mit 200 bis 300 neuen Dauerpatienten pro Praxis. Im Interview erläutert Präsidiumsmitglied Erika Baum, wie Hausärztinnen und Hausärzte am besten vorgehen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Radiotherapy Versus Partial Penectomy for T1 Squamous Cell Carcinoma of the Penis